A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

📅 15/03/2026 19:39 📰 fool 👁️ 9 lectures 🌍 États-Unis 📂 Économie

This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.